Geode Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.34M Buy
603,524
+42,615
+8% +$105K ﹤0.01% 3066
2025
Q4
$1.09M Buy
560,909
+7,307
+1% +$12K ﹤0.01% 3348
2025
Q3
$468K Hold
553,602
﹤0.01% 3650
2025
Q2
$401K Sell
553,602
-597,420
-52% -$449K ﹤0.01% 3625
2025
Q1
$991K Buy
1,151,022
+8,480
+0.7% +$12.6K ﹤0.01% 3307
2024
Q4
$1.92M Buy
1,142,542
+7,000
+0.6% +$16.7K ﹤0.01% 3142
2024
Q3
$3.24M Buy
1,135,542
+811
+0.1% +$2.1K ﹤0.01% 2958
2024
Q2
$2.66M Buy
1,134,731
+27,780
+3% +$72.5K ﹤0.01% 3036
2024
Q1
$3.25M Buy
1,106,951
+41,697
+4% +$118K ﹤0.01% 2913
2023
Q4
$3.19M Buy
1,065,254
+50,687
+5% +$145K ﹤0.01% 2919
2023
Q3
$3.21M Buy
1,014,567
+8,101
+0.8% +$26.4K ﹤0.01% 2868
2023
Q2
$3.9M Buy
1,006,466
+12,780
+1% +$36.8K ﹤0.01% 2826
2023
Q1
$2.75M Buy
993,686
+32,818
+3% +$68.8K ﹤0.01% 2902
2022
Q4
$1.73M Buy
960,868
+5,799
+0.6% +$11.2K ﹤0.01% 3109
2022
Q3
$2.02M Buy
955,069
+4,290
+0.5% +$10.8K ﹤0.01% 3078
2022
Q2
$2.56M Buy
950,779
+424,473
+81% +$1.58M ﹤0.01% 3027
2022
Q1
$2.28M Buy
526,306
+31,108
+6% +$128K ﹤0.01% 3196
2021
Q4
$2.56M Buy
495,198
+109,327
+28% +$585K ﹤0.01% 3256
2021
Q3
$2.37M Buy
385,871
+320,474
+490% +$2.55M ﹤0.01% 3274
2021
Q2
$660K Buy
+65,397
New +$708K ﹤0.01% 3808

Other funds holding NAUT

Geode Capital Management's NAUT Position: Q1 2026 in Review

Geode Capital Management increased its Nautilus Biotechnolgy (NAUT) stake by 7.6% in Q1 2026, buying an estimated $105K and bringing the position to 603,524 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Geode Capital Management first reported a position in NAUT in Q2 2021 and has held it in 20 quarters since. The position peaked at $3.9M in Q2 2023. 81 funds tracked by Wall St. Rank hold NAUT as of Q1 2026.

  • Geode Capital Management held 603,524 shares of Nautilus Biotechnolgy worth $2.34M as of Q1 2026.
  • Geode Capital Management bought 42,615 Nautilus Biotechnolgy shares in Q1 2026, an estimated $105K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3066 holding.
  • Geode Capital Management first reported a position in Nautilus Biotechnolgy in Q2 2021 and has held it in 20 quarters since.
  • Geode Capital Management's Nautilus Biotechnolgy position peaked at $3.9M in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.